Sox9 neural crest determinant gene controls patterning and closure of the posterior frontal cranial suture

David E. Sahar, Michael T. Longaker*, Natalina Quarto*

Department of Surgery, The Children's Surgical Research Program, Stanford University School of Medicine, 257 Campus Drive Meyer Building, Stanford University, Stanford, CA 94305-5148, USA

Received for publication 8 July 2004, revised 19 January 2005, accepted 19 January 2005

Abstract

Cranial suture development involves a complex interaction of genes and tissues derived from neural crest cells (NCC) and paraxial mesoderm. In mice, the posterior frontal (PF) suture closes during the first month of life while other sutures remain patent throughout the life of the animal. Given the unique NCC origin of PF suture complex (analogous to metopic suture in humans), we performed quantitative real-time PCR and immunohistochemistry to study the expression pattern of the NCC determinant gene Sox9 and select markers of extracellular matrix. Our results indicated a unique up-regulated expression of Sox9, a regulator of chondrogenesis, during initiation of PF suture closure, along with the expression of specific cartilage markers (Type II Collagen and Type X Collagen), as well as cartilage tissue formation in the PF suture. This process was followed by expression of bone markers (Type I Collagen and Osteocalcin), suggesting endochondral ossification.

Moreover, we studied the effect of haploinsufficiency of the NCC determinant gene Sox9 in the NCC derived PF suture complex. A decrease in dosage of Sox9 by haploinsufficiency in NCC-derived tissues resulted in delayed PF suture closure. These results demonstrate a unique development of the PF suture complex and the role of Sox9 as an important contributor to timely and proper closure of the PF suture through endochondral ossification.

© 2005 Elsevier Inc. All rights reserved.

Keywords: Neural crest cells; Sox9; Chondrogenesis; Endochondral ossification; Cranial suture patterning; Posterior frontal suture

Introduction

Calvaria origin can be traced back to the neural crest and paraxial mesoderm. The frontal bone plates and the PF suture (analogous to metopic suture in humans) originate from NCC in vertebrates (Coully et al., 1993; Jiang et al., 2002; Le Lievre, 1978; Morriss-Kay, 2001; Noden, 1975). Normal craniofacial development is dependent on precise tissue contributions by the NCC and paraxial mesoderm and controlled gene regulation of sutures positioned between the calvarial growth fronts.

Aberration at any control level could potentially lead to premature suture closure (craniosynostosis) or delayed suture closure (Opperman, 2000; Rice et al., 2003; Wilkie, 1997).

Since the first report of a genetic link to craniosynostosis in 1993 (Jabs et al., 1993), heterozygous mutations in at least 6 different genes have been associated with this condition; fibroblast growth factor receptors (FGFRs), Transcription factors MSX2 and TWIST, and Fibrillin-1 (Bellus et al., 1996; Howard et al., 1997; Meyers et al., 1996; Muenke et al., 1994; Sood et al., 1996). Expression and interaction of Fgfrs, Msx2, and Twist genes have been described extensively in murine cranial sutures (Igelzi et al., 2003; Iseki et al., 1997, Ishii et al., 2003; Rice et al., 2003; Warren et al., 2003). However, sporadic cases of craniosynostosis, without an identified gene mutation, constitute the majority of children with craniosynostosis (Gorlin et al., 1990; Wilkie and Morriss-Kay, 2001). The sporadic cases suggest a larger repertoire of genes involved in normal suture development.

The PF suture is the only suture whose mesenchyme and flanking calvarial bone plates are derived from NCC. Since this is the only cranial suture that closes during the lifetime of
mice, it warrants the question of whether the unique origin of this suture complex is responsible for its distinctive fate. To date, no analytical study of PF suture development in mice has been reported. Since, the closing PF suture complex in mice is of neural crest origin, NCC determinant genes may contribute to its unique fate.

**Sox9**, a transcription factor and a member of group E sox genes, is a NCC determinant gene as well as a direct regulator of chondrogenesis (Akiyama et al., 2002; Bi et al., 2001; Cheung and Briscoe, 2003; de Crombrugghe et al., 2000; Mori-Akiyama et al., 2003; Spokony et al., 2002). Heterozygous mutations in **SOX9** in humans lead to campomelic dysplasia (CD), a severe dwarfism syndrome characterized by anomalies of endochondral skeleton elements (Foster et al., 1994; Wagner et al., 1994). Heterozygous mutation of **Sox9** in mice causes craniofacial anomalies resembling CD patients (Bi et al., 2001). **Slug**, a zinc-finger transcription factor and a member of the Snail family, is expressed in migratory NCC (Jiang et al., 1998; Nieto et al., 1994). To date, there has been no study examining NCC markers **Sox9** or **Slug** and their down-stream targets in closing and patent sutures.

In mice and rats, the PF suture closes during the first month of life, while the sagittal (SAG) and coronal (COR) sutures remain patent throughout the life of the animal (Bradley et al., 1996; Moss, 1958; Opperman, 2000). The divergent suture fate, along with availability of transgenic lines in mice, makes this model ideal for studying suture development and biology. The temporal sequence of suture mesenchyme ossification and its genomic expression pattern is not well characterized in mice. In this study, we have analyzed histologically and morphologically the temporal sequence of events during the first month of life in PF suture complex. Moreover, we have investigated the expression of NCC markers **Sox9** and its target genes, as well as **Slug** in the NCC derived PF suture. Finally we have analyzed the PF suture complex in mice that are **Sox9** conditionally haploinsufficient in NCC derived tissues.

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Animals and generation of mutant mice**

The animals were cared for in accordance with the Institutional Animal Care and the Use Committee at Stanford University. **Sox9**

**Materials and methods**

**Materials and methods**

1 litter (on average 8 animals) of mice was used for each time point. Pooled sutures from each litter were homogenized in 0.6 ml of Trizol (Invitrogen, Carlsbad, CA) using a Pellet Pestle Motor, (Kontes) according to manufacturer’s protocol. RNA was extracted and precipitated using chloroform and 2-propanol. RNA was further washed with DEPC treated 70% ethanol. RNA was isolated from three independent litters of mice.

**Tissue processing and staining**

Following sacrifice of animals described above, the calvariae of animals were harvested and immediately fixed in fresh, chilled 4% paraformaldehyde overnight at 4°C followed by 24 to 48 h of decalcification in Formical-2000 (Decal Chemical Company, Congers, NY). Each calvaria was divided coronally through the bregma to separate the PF from the SAG sutures. The specimens then underwent dehydration in a graded ethanol series and were paraffin embedded. The entire blocks were serially sectioned (5–7 μm) totaling approximately 400 sections for each block. Every other slide was stained with hematoxylin and eosin (H&E) for evaluation and the selected slides were used for immunohistochemistry and Safranin-O. H&E and Safranin-O staining were performed according to standard procedures. The stained sutures
were examined with Carl Zeiss Axioplan 2 (Zeiss, Thornwood, NY) microscope from 10× to 100× magnification. Images were captured by AxioVision (Zeiss, Thornwood, NY) and combined by Adobe Photoshop (Adobe Systems, San Jose, CA). Closure was defined as mature bony bridge between the osteogenic fronts.

Morphometric analysis

For gross morphometric analysis, fixed whole calvariae were stained overnight in 0.1% Alizarin red and/or Alcian blue according to standard procedures, followed by clearing with 50% Glycerol for 2–4 weeks. Measurements were made in triplicate per time point using a caliper and a ruler. Skull length was measured from the anterior margin of frontal bone to the posterior margin of occipital bone. Skull width was defined as the maximum length between the lateral aspect of parietal bones as seen from top view. The PF suture measurement was made from jugum limitans (landmark between PF and AF sutures) to bregma (confluence of SAG, COR and PF sutures). The SAG suture was measured from the bregma to the lambdoidal suture.

Quantitative real-time PCR

Purified and quantified RNA were treated with DNase I (Ambion, Austin, TX) to clear genomic DNA. 5 μg of total RNA from each time point was reverse transcribed to cDNA using random primer hexamers (Invitrogen, Carlsbad, CA). For quantitative real-time PCR, primers were designed with Primer Express™ software (Applied Biosystems). Each primer was subjected to PCR to ensure single primary amplicon as evidenced by 2% agarose gel electrophoresis to be ≤200 bp for maximum efficiency. SYBR® Green PCR Master Mix (Applied Biosystems) was used for fluorescence. Primer sequences used: Sox9, (F: ACGGCTCCAGCAAGAACAA; R: TTGTGCAATGGCGGTACTG); Slug, (F: CCACTGGAAGTGAATTTCA; R: CCCAGGCTCACTATTCCCTGT); Type I Collagen (F: AAACCGAGGTAGCTGTGATCT; R: CCAGTTCTTCAATTGCATTGC); Type II Collagen (F: CGAGTGGAGAGCCGGAGACTAC; R: CCAGTTTTTCGGAGGACGT); Type X Collagen (F: TGCTGCCTCAAATACCTTTCT; R: TGGGCTATGGGATGAAGTATTG); Fgf-2 (F: GTCACGGGAAATACCTCAGTTGTG; R: CCCGTTTTGATCCGAGTTT); Fgf-18 (F: CAAAGTCTCGGCGCTAGA; R: GCCCTTGGATCCGACCTGA); Osteocalcin (F: GGAGACCGACAGGAGAAC; R: CAGGCTCTGCGAGATCTC), Samples along with primers and Syber Green Master Mix (Applied Biosystems, Foster City, CA) were loaded in 384 well sealed plates and the reaction was run in an ABI Prism 7900 HT (Applied Biosystems) according to the manufacturer’s protocol. Gapdh (Applied Biosystems) was used for internal control.

Standard curve method of quantitation was used to calculate expression of target genes relative to the housekeeping gene Gapdh. Four serial dilutions of cDNA (1:4) were made for the calibration curve and trend lines were drawn using Ct values versus log of dilutions for each target gene and Gapdh run in triplicate with correlation coefficient ($R^2 > 0.99$). Relative expressions were calculated using line equations derived from calibration curves and obtaining ratios of target gene to Gapdh for each time point. For each gene, experiments were run at least three times using three independent litters of mice. The error bars reflect variability between litters.

Immunohistochemistry

Selected paraffin embedded sections were chosen, deparaffinized, rehydrated and antigen retrieval was performed. For extracellular matrix antigens, sections were treated with pepsin (Sigma, St. Louis, MO) for 1 h at 37°C. The Vectastain ABC system (Vector Laboratories, Burlingame, CA) was used according to the manufacturer’s protocol for immunoperoxidase detection of targeted antigen. Primary antibodies against Sox9, Slug and Type II Collagen (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), Osteocalcin (Biomedical Technologies Inc., Stoughton, MA) and Type X Collagen (Quartett Immunoagnostika and Biotechnologie, Berlin, Germany) were used in serial dilutions (1:50, 1:100, 1:200). Appropriate biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA) were used in 1:500 dilutions. Non-specific serum of primary antibody host species was used as negative control.

Results

PF and SAG suture characteristics during the first month of life

Current understanding of suture biology suggests involvement of all three suture complex components in suture closure; osteogenic fronts, mesenchyme, and the underlying dura mater (Greenwald et al., 2001; Opperman et al., 1993; Roth et al., 1996). As such, all three components above will form our experimental model. This complex lies between bregma posteriorly and jugum limitans anteriorly (Figs. 1A and B). To study physical characteristics of the PF and SAG sutures during development in mice, we performed morphometric analysis on Alizarin red/Alcian blue stained calvariae during the first month of life in timed birth mice. Morphometric analysis demonstrated that calvaria length and width growth is greatest during the first 2 weeks of life, however, the calvaria continues to grow thereafter at a slower pace during third and fourth week of life (Fig. 1C). Calvaria length increases from 8.5 to 14 mm while calvarial width increases from 7 to slightly over 11 mm from birth to 25 days of age. To determine the intrinsic growth of the PF and SAG sutures we measured the length of suture itself, based on well-known anatomical landmarks...
encompassing the sutures. The anterior landmark for the PF suture is the jugum limitans. The posterior landmark for the PF suture, as well as the anterior landmark for the SAG suture is the bregma, where COR suture transects between the PF and SAG sutures. The posterior landmark for the SAG suture is the lambdoidal suture (see Fig. 1A).

As it turns out, the PF suture growth is relatively steady during the growth of calvaria throughout the first month of life. However, the SAG suture grows rapidly before closure of the PF suture, then it slows down to a rate similar to the PF suture after closure is initiated. There is a temporal relationship between PF closure and growth rate of the SAG suture (pre and post closure rate). The PF suture is longer (24% of calvarial length at p1) than the SAG suture (13% of calvarial length at p1) during the first 5 days of life; however, this relationship changes quickly after the first 5 days of life due to rapid growth of the SAG suture during this period. The PF suture length contributes significantly to the length of the calvaria during the first 5 days of life. After the first 5 days of life, the SAG suture contributes more as its growth exceeds that of the PF suture (Fig. 1D).

The PF suture length postnatally ranges from 2 mm on p1 to 3 mm on p25, while the SAG suture ranges from 1.2 mm to approximately 4 mm during the same period. Moreover, during the first 2 weeks of life, the intrinsic growth of PF suture increases approximately by 25%, while the intrinsic growth of SAG suture increases approximately by 340% (data not shown).

Since the PF suture is the only calvarial suture in mice that closes during the first month of life, we next investigated the precise window of time when closure takes place, in order to analyze the expression profile and potential functional role of select neural crest determinant genes. Because histology is a successful technique for assessing cranial suture morphology and fate, serial coronal sections of PF sutures were obtained during the first month of life for detailed examination of this suture. As seen in Fig. 2A, evidence of PF suture changes preceding closure was seen as early as p7 in the form of cellular condensation in suture mesenchyme. However, an overt ossified bony bridge was not seen until p9–p10. This process started anteriorly in the PF endocranial layer and proceeded posteriorly. PF suture closure was largely completed by p15. Importantly, the ectocranial layer of PF suture remained patent out to the end of our study, time point (p25), and beyond (p240) (data not shown).
The timing of the mouse PF closure presented here is earlier than what was previously reported (Bradley et al., 1996). A likely explanation for this discrepancy in timing lies in the nature of PF suture: intermittent points of closure alternate with patency areas, resulting in regions where the PF suture has closed and regions where it remains open (Fig. 4B).

**PF suture development is unique**

The difference between the PF suture and other cranial sutures goes beyond embryonic tissue origin. Although previous studies have treated the PF suture as either closing or non-closing (Bradley et al., 1996; Moss, 1958; Opperman, 2000), detailed studies of this suture revealed a more sophisticated architecture. The PF suture is comprised of a double layer interface stacked on top of each other: the ectocranial and endocranial layers (Fig. 2B). Our observation is in agreement with a study performed by Moss on rat PF sutures. Moss in his early histological study on PF sutural closure, described the following: “Ect- and endocranial plates of bone were clearly discernible. The sutural edges of the thin lamellar ectocranial plates of the frontal never fused” (Moss, 1958). All other cranial sutures, including SAG and COR sutures, form a single sutural interface between approaching calvarial plates (Fig. 2B). The ectocranial layer, overlying the endocranial layer, consists of a fibrous suture mesenchyme, the osteogenic fronts and the overlying periosteum. This layer, which can be seen from top view of skull (Fig. 1B), is contiguous with the SAG suture posteriorly at the bregma and the AF suture anteriorly at the landmark line, jugum limitans. Similar to SAG and COR sutures, the PF ectocranial layer remains patent throughout life. What makes the PF suture unique is the endocranial layer (Fig. 2B). Importantly, as shown in Fig. 2B, the closing endocranial PF layer is not present in both SAG or in COR sutures, which are known to be patent throughout life. Another difference between the PF, SAG and COR sutures is the presence of suture vein between the ectocranial and endocranial layers (Fig. 1B).

Histochemistry analysis of PF suture performed on embryos revealed at E14 only the presence of the sagittal sinus, while both the ectocranial and endocranial layers were not yet formed at this stage (Fig. 2C). At E18, the ectocranial layer was visible (Fig. 2D). In contrast, the endocranial layer and PF vein were not yet present at these stages (Fig. 2D). At p1, both ectocranial and endocranial layers of the PF suture were well defined, and the sagittal sinus was present, while the PF vein was still not visible (Fig. 2E). The PF vein was clearly detected between the approaching endocranial osteogenic fronts at p7 (Fig. 2F).

**Neural crest markers Sox9 and Slug are upregulated during PF suture closure**

The unique PF suture development described above was likely a result of differential gene expression at the suture complex level. Given the distinct neural crest origin of the PF suture complex, we asked what was the expression profile of NCC genes such as Sox9 and Slug during closure of the PF suture. After determining the precise timing of PF suture closure, we analyzed the expression profile of Sox9 in the NCC-derived PF suture. We performed quantitative real-time PCR on the PF suture complex during the first month of life (Fig. 3A). Expression of Sox9 was noted to increase by p7 and peak on p9/p10, before returning to baseline on p13. Next, to define the precise spatial localization of Sox9 protein during this time period, we performed immunohistochemistry using a Sox9-specific antibody on serially timed PF suture sections. As shown in Fig. 3B, nuclear localization of Sox9 protein was detected in the PF suture as early as p7. Maximal levels of Sox9 protein was observed on p9. Interestingly, Sox9 protein immunostaining was detected only on alternate sets of histological sections derived from the entire PF suture, and corresponding to regions undergoing closure.

To examine expression of Slug during PF suture closure, we performed quantitative real-time PCR followed by immunohistochemistry on PF suture during the time of closure using a Slug specific antibody. Our results indicated a maximal expression of Slug on p9 at both mRNA and protein levels (Figs. 3C and D).

Interestingly, no up-regulation of Sox9 expression was noted at anytime during the first month of life in the SAG suture (Figs. 3E and G) as well as in the AF suture (data not shown). These results indicated that expression of Sox9 tightly correlated with areas of suture closure, indeed suggesting a potential role of Sox9 in PF suture closure. Unlike Sox9, however, up-regulation of Slug gene expression was observed in SAG suture at the time when PF suture closure occurs (Fig. 3F).

Fig. 2. Analysis of PF suture closing time and morphogenesis. A, H&E histochemistry analysis of PF suture from p1, p5, p9, p11, p13, p15, p17, p25 reveals bony closure during the second week of life. The PF suture mesenchyme (arrow, p1) in mice undergoes initial closure between p9 and p11 and completes this process by p15–17. Note, only the endocranial layer of PF suture is closed by p25 (arrow), while the ectocranial layer (arrowhead) is still open. This layer remains patent throughout life-time (data not shown). B, comparative structural analysis of PF, SAG and COR suture at p9. The PF suture complex is comprised of two (endocranial and ectocranial) layers separated by a vein and connective tissues, while both SAG and COR suture form a single layer between the approaching cranial plates. C, H&E histochemistry analysis of PF suture from E14 reveals only the presence of the sagittal sinus. D, at E18, the ectocranial layer of PF suture is detected (right columns represent higher magnification of the suture sections). E, at p1, both ectocranial and endocranial layers of the PF suture are well defined, while the PF vein is not yet detected. F, at p7, the PF vein is clearly visible between the approaching endocranial osteogenic fronts. Abbreviations used: (F, frontal bone; OFs, osteogenic fronts; PFFect, PF ectocranial layer; PFend, PF endocranial layer; P, parietal; M, mesenchyme; PO, periosteum; DM, dura-mater; SS, sagittal sinus; PSV, PF suture vein) (magnification at 63×).
Sox9 gene expression domains control chondrogenesis in PF suture

In addition to its neural crest determining role, Sox9 is also a master regulator of chondrogenesis (Akiyama et al., 2002; Bi et al., 2001; de Crombrugghe et al., 2000; Mori-Akiyama et al., 2003; Wright et al., 1995). The presence of Sox9 expression in the PF suture during closure suggested chondrogenesis might be taking place. To verify this possibility, we analyzed serial sections of PF suture using Safranin-O staining which detects negatively charged glycosaminoglycan (GAG) production (Fig. 4A). Cell condensation, a process preceding chondrogenesis (Haas and Tuan, 1999), was noted within the mesenchyme of the endocranial layer of the PF suture as early as p7, while overt maximal chondrogenesis and Safranin-O-positive staining was observed between p8 and p9, followed by hypertrophy of chondrocytes at p10 (Fig. 4A). Minimal, if any, cartilaginous tissue was noted by p13. No cartilage formation was noted in the ectocranial layer of PF suture during this time. Immunohistochemistry using Sox9 antibody detected, as expected, co-localization of Sox9 protein in the areas of chondrogenesis. Intriguingly, chondrogenesis, as well as Sox9 protein immunostaining was detected only on alternate sets of histological sections derived from the entire PF suture. This observation suggested that chondrogenesis might not be occurring through the entire region of the PF suture.

To verify this possibility, Alcian blue staining of whole-mount calvaria was performed to analyze chondrogenesis in the calvaria skull vault (Fig. 4B). Initial chondrogenesis domains were observed anteriorly in the PF suture at points of contact (joints) between the approaching frontal bones as early as p8. By p9, multiple centers of chondrogenesis were seen anteriorly followed by closure of the suture and loss of cartilage by p11–p12. Thus, chondrogenesis was not present throughout the entire PF suture, rather it was noted in intermittent areas alternated with areas of patency (gaps) which were negative for Alcian blue staining. To examine also the expression of Sox9 and its target gene Col II in these patent areas (gaps) of PF sutures, we performed immunohistochemistry on sections derived from these areas using a Sox9 specific antibody (Fig. 4C). No Sox9 or Type II Collagen protein was detected in these areas, thus confirming the presence of Sox9 and chondrogenesis associated with area of PF suture closure and not areas of suture patency.

Sox9 regulates the expression of cartilage specific extracellular matrix molecules, Type II Collagen (Col II) (Bell et al., 1997; Lefebvre et al., 1997) and Type X Collagen (Col X) (Zehentner et al., 1999). To confirm this relationship in the closing PF suture complex, quantitative real-time PCR was performed for both of these extracellular matrix molecule genes. Col II and Col X expression was maximal on p9 and p10, respectively (Figs. 5A and C). While Col II returned to baseline by p11, Col X remained high on this time point and returned to baseline by p13. This temporal Col X expression pattern is consistent with its known pattern of expression in hypertrophic cartilage. To analyze Col II and Col X protein levels in closing PF sutures, we performed immunohistochemistry on PF sutures at serial time points using Col II- and Col X-specific antibodies. Col II and Col X proteins (Figs. 5B and D) were localized to the endocranial layer of PF sutures on p9 and p10, corresponding to their transcriptional expression time points. Taken together, these data indicated chondrogenesis in the endocranial layer of PF sutures prior to closure.

PF suture closes through endochondral ossification

To assess the fate of cartilage present in the PF suture and verify possible endochondral ossification occurring during PF suture closure, we analyzed the expression of bone markers Type I Collagen (Col I) and Osteocalcin in the PF suture complex. During the first week of life where rapid growth of skull was observed, Col I was up-regulated (Fig. 6A). Upon onset of closure of PF suture and chondrogenesis, Col I was sharply down-regulated, but was up-regulated again during ossification of the PF suture with peak expression on p13, returning to baseline by p17. Osteocalcin, a marker of terminally differentiated osteoblasts, was maximally expressed during the late period of PF suture closure (Fig. 6B). An increase in Osteocalcin expression was noted on p13 with maximum expression on p15, returning to baseline by p17. We performed immunohistochemistry using Osteocalcin specific antibody to detect the corresponding level of Osteocalcin protein product. In the PF suture up to p9, a low amount of Osteocalcin staining was seen between the osteogenic fronts (Fig. 6C). Starting with p11, this area revealed increased Osteocalcin protein staining. By p13 the intensity of Osteocalcin immunostaining in the PF suture was equivalent to the surrounding bony structures signifying a complete bony bridge between the osteogenic fronts. Thus, the expression of both Col I and Osteocalcin in the same area of PF suture where we previously showed cartilage formation, strongly suggested the occurrence of endochondral ossification of this suture.

Expression of Fgf-2 and Fgf-18 during suture closure

The observation of unique Sox9 expression as well as chondrogenesis during initiation of PF suture fusion prompted us to investigate the expression of potential regulators of Sox9 gene during the period of suture closure. Murakami et al. (2000) demonstrated a MAP kinase mediated Sox9 up-regulation by FGF-2 in chondrocytes and undifferentiated mesenchymal cultured cells. Moreover, in vitro studies showed chondrogenic differentiation of premigratory NCC with exogenous FGF-2 stimulation (Sarkar et al., 2001). On the contrary, FGF-18, a regulator of cell proliferation and differentiation, negatively affects chondrogenesis while positively affecting osteogenesis (Ohbayashi et al., 2004). Since the NCC-derived PF suture complex undergoes transient chondrogenesis followed by osteogenesis, we...
investigated whether Fgf-2 gene expression would temporally coincide with the chondrogenesis phase, while Fgf-18 gene expression would coincide with the osteogenesis phase of PF suture closure. To address this question, we analyzed the expression of Fgf-2 and Fgf-18 in the PF suture complex during the first month of life using quantitative real-time PCR. Interestingly, we observed that Fgf-2 and Sox9 genes were temporally co-expressed in the PF suture complex. Maximum expression of Fgf-2 was observed on p9, a time when expression of Sox9 and chondrogenesis occurred (Fig. 7A). Only baseline expression of Fgf-2 was noted in SAG suture during the same period (Fig. 7C). These results demonstrated temporal co-expression of Fgf-2, a potential regulator of Sox9 and chondrogenesis in the PF suture. In contrast, an increased level of Fgf-18 expression was observed on p11–p13, the most active period of suture closure in the PF suture.
closure and osteogenesis (Fig. 7B). Fgf-18 expression was decreased by p15, when closure was mostly completed. These results demonstrated that members of the FGF family which are known as positive regulators of both chondrogenesis and osteogenesis are expressed in a temporo-spatial pattern consistent with the PF suture closure. Therefore, we speculate that FGF-2 may control the expression of Sox9 and chondrogenesis during PF suture closure, whereas FGF-18 may control osteogenesis.

The diagram in Fig. 7D summarizes the temporal gene expression profiles and differentiation events occurring during the closure of PF suture.

**Analysis of PF suture phenotype in Sox9 conditional knock-out mice**

Because of the unique and controlled expression pattern of Sox9 gene at both message and protein levels during PF suture closure we sought to determine whether Sox9 could play a role in PF suture closure. Indeed, we investigated whether a depletion of cartilage formation would affect the fate of PF suture closure. To answer our question we analyzed the PF suture phenotype in Sox9-deficient mice in vivo. This analysis would give us insight into the functional importance of Sox9 during PF suture closure. Homozygous or heterozygous loss of function mutations in Sox9 gene are not compatible with life (Bi et al., 2001). Therefore, we used the Cre recombinase/loxP (Cre/loxP) system (Gu et al., 1994) to develop a Sox9-insufficient state selectively in NCC derived tissues using mice harboring Wnt1-Cre transgene and a floxed Sox9 allele (Akiyama et al., 2002). Since complete loss of Sox9 in NCC-derived tissue is lethal perinatally (Mori-Akiyama et al., 2003), this mutant would preclude our study which requires survival during the first 2 weeks of life. However, haploinsufficiency of Sox9 in NCC derived tissue is viable (Mori-Akiyama et al., 2003). We obtained haploinsufficient Sox9^{floxed/WT;Wnt1-Cre} mice by crossing Sox9^{floxed/WT} female mice with Wnt1-Cre male mice (Fig. 8A). Heterozygotic mice harboring Sox9^{floxed/WT;Wnt1-Cre} were viable and fertile, although with significant perinatal mortality compared to controls. Sox9^{floxed/WT;Wnt1-Cre} and control littermates were sacrificed on p10, the onset of PF
suture closure. Whole fresh calvariae of mutant mice examined under a stereo-microscope revealed hypoplastic craniofacial skeleton and a smaller domed shape skull (Fig. 8A). The PF cranial sutures in mutants were grossly patent, as seen under low power field in Fig. 8A, while control groups had already begun the process of closure by forming points of contact anteriorly. We then analyzed the p10 PF suture complex sections using H&E and Safranin-O staining. In mutant mice (n = 12), the endocranial layer of PF suture was widely patent on p10, while the WT group (n =

Fig. 4. Chondrogenesis precedes PF suture closure. A, histological analysis of the PF suture obtained from specific areas (joint repeats) of PF suture using Safranin-O staining revealed proteoglycan staining of the PF suture evident as early as p7–p8 and peak on p10. No staining is detected by p13. (Middle column represents higher magnification of the boxed areas). Note, co-localization of proteoglycan staining with Sox 9 protein in the area of condensing endocranial mesenchymal cells in the PF suture between osteogenic fronts. B, Alcian blue staining of whole-mount calvariae reveals initial points of chondrogenesis visible as early as p8 on the anterior part (A) of the PF suture. More areas of chondrogenesis are noted on subsequent days with peak between p9 and p10 in the posterior part (P) of the PF suture. C, immunohistochemistry analysis of tissue sections derived from the patent areas (gap repeats) of PF suture on p7 and p9 does not reveal any Sox 9 protein as well product of its target gene Col II.
12) exhibited initiation of closure through thickening and chondrogenesis (Fig. 8B). There was also a decrease in calvarial bone thickness, especially in the PF suture area, compared to the WT mice. By p15 complete closure of PF suture was observed in WT mice ($n = 6$). In contrast, Sox9$^{flox/WT;Wnt1-Cre}$ mice ($n = 7$) still showed lack of PF suture closure. These results were seen in over 90% of Sox9$^{flox/WT;Wnt1-Cre}$ mutants indicating a high penetrance of this phenotype. However, histological analysis of PF suture in older animals (p35) showed only an impaired closure of PF suture for Sox9$^{flox/WT;Wnt1-Cre}$ mutant mice (data not shown). In addition, we performed Alcian blue staining of whole-mount calvariae on Sox9$^{flox/WT;Wnt1-Cre}$ to analyze the patterning of chondrogenic domains within the PF suture previously observed in WT mice (Fig. 4B). As shown in Fig. 8C at p9, the timing when multiple chondrogenic domains are present in WT mice, none of these domains where detected in Sox9$^{flox/WT;Wnt1-Cre}$ mice during the same time points. Thus, in Sox9$^{flox/WT;Wnt1-Cre}$ mutant mice, the distinct patterning of PF suture preceding its closure was lost. Taken together, the above results suggest an important role for Sox9 in PF suture patterning and timing of closure.

**Discussion**

Calvaria origin can be traced back to neural crest and paraxial mesoderm. The frontal bone plates and the PF suture (analogous to metopic suture in human) originate from NCC in vertebrates (Couly et al., 1993; Jiang et al., 2002; Le Lievre, 1978; Morriss-Kay, 2001; Noden, 1975). Thus, the PF suture is the only suture derived solely from the NCC and flanked by calvarial plates on both sides derived from NCC. Since this is the only cranial suture that closes during the lifetime of mice, it warrants the question of whether the unique origin of this suture complex is responsible for its unique fate. To date, no analytical study of PF suture development in mice has been reported. In this study, we have analyzed the morphogenesis and events related to the closure of posterior frontal (PF) suture in mice. Using the PF sutural complex as a model system, we investigated the timing and morphological changes leading to suture closure as well the expression and functional role of the neural crest determinant gene Sox9 during suture closure.

**Biological significance of neural crest determinant genes Slug and Sox9 expression in the PF suture**

Much attention has been given to the expression of several genes in coronal and sagittal sutures, including FGF receptors and ligands, BMP ligands, transcription factors Msx and Twist (Kim et al., 1998; Liu et al., 1999; Rice et al., 2000). Because of its entirely neural crest origin, we analyzed the expression of NCC determinant genes Slug and Sox9 in the PF cranial suture during the time when the suture closure occurs. The expression analysis demonstrated that there was a unique expression profile for Sox9 gene in the PF suture during the time of closure.

This observation is particularly interesting and would suggest that Sox9 plays a unique and perhaps essential role in the development and fate of the PF suture. Furthermore, the differential expression of Sox9 in the PF cranial suture indicates execution of a distinct morphogenetic program for this suture. Analysis of whole-mount skulls stained with Alcian blue revealed that the pattern of closure of the PF suture is characterized by the presence of areas of closure alternated with areas of patency ("joint-gap" repeats), where closure areas are marked by Sox9 gene expression as well as
cartilage positive domains. We believe that the “unique” recapitulation of Sox9 during the time of PF suture is of biological importance and sets up the conditions for endochondral ossification leading to PF suture closure, as haploinsufficiency of Sox9 gene caused a delay in suture closure due to impaired cartilage formation. We hypothesize that the upregulated expression of Sox9 within the suture mesenchyme prior to PF suture closure directs a differentiation decision, biasing neural crest cells toward chondrocytes. In support of this hypothesis is the recent work by Cheung and Briscoe (2003) which demonstrated that neural crest development is regulated by Sox9 and that Sox9 acts at two stages of neural crest differentiation: first as an intrinsic determinant of neural crest, initiating neural crest develop-

Fig. 5. Expression of cartilage markers Col II and Col X in the PF suture complex. A, quantitative real-time PCR shows that Col II expression was maximal on p9 with return to baseline by p11. B, immunohistochemistry shows maximum type II collagen protein on p10. Starting from p11 type II collagen immunostaining decreased. No protein was detected by p13. C, quantitative real-time PCR showed Col X expression was maximal on p10 with return to baseline by p13. D, immunohistochemistry showed maximum type X collagen protein antigen by p10 in the endocranial mesenchyme of PF suture with residual amount on p13 (magnification at 63×).
ment and segregating this lineage from neuroepithelium, and subsequently directing differentiation decisions in the periphery, biasing neural crest cells to glial cell and melanocyte lineages and away from neuronal fate. We believe that the expression of \textit{Sox9} in the mesenchymal cells within the PF suture area leads to their differentiation into chondrocytes, and therefore, the PF suture closes eventually through an endochondral ossification process. Therefore, we propose that the PF suture closure may be controlled during postnatal calvarial development by the up-regulation of neural crest determinant gene \textit{Sox9} which promotes cartilage formation as an intermediate step preceding calcification and bony bridge formation defining suture closure. It is likely that \textit{Sox9} specifies the mesenchymal cells in the PF suture to become cartilage, but what are the factors responsible for the unique induction of \textit{Sox9} expression in this region of calvarial suture? What is the signaling pathway triggering the up-regulation of \textit{Sox9}? Is there positional information that instructs neural crest-derived cells present in the PF suture to up-regulate \textit{Sox9} gene expression, or is there an intrinsic capacity of these specific neural crest-derived cells to recapitulate the expression of \textit{Sox9}? Why do mesenchymal neural crest-derived cells present within the SAG suture, which remains patent throughout life, not express \textit{Sox9} gene although they express other neural crest determinant genes such as \textit{Slug}? These are all challenging, as well as fascinating questions that deserve answers. The fact that only the neural crest-derived cells present in the PF suture to up-regulate \textit{Sox9} gene expression, or is there an intrinsic capacity of these specific neural crest-derived cells to recapitulate the expression of \textit{Sox9}? Why do mesenchymal neural crest-derived cells present within the SAG suture, which remains patent throughout life, not express \textit{Sox9} gene although they express other neural crest determinant genes such as \textit{Slug}? These are all challenging, as well as fascinating questions that deserve answers. The fact that only the neural crest-derived cells present in the PF suture are able to recapitulate the expression of \textit{Sox9} gene would suggest that positional inductive signal(s) rather than a cell-autonomous event is responsible for the unique expression of \textit{Sox9} in the PF suture. It is known that various members of the FGF superfamily, in particular FGF-2 up-regulates the expression of \textit{Sox9} in chondrocytes (Murakami et al., 2000). Our data demonstrate a co-expression of \textit{Fgf-2} and \textit{Sox9} within the PF suture. In contrast, \textit{Fgf-2} is not expressed at the same time points in the SAG suture. In light of these results, it is
tempting to speculate that FGF-2 may be one of candidate molecules controlling the expression of Sox9 gene during PF suture closure.

**Posterior frontal suture closure occurs through endochondral ossification**

Bone development occurs by intramembranous or endochondral ossification. Intramembranous ossification involves direct osteogenesis from mesenchymal cells without the intermediate participation of cartilage. In contrast, endochondral ossification occurs within a cartilage model in which chondrocytes undergo hypertrophy and apoptosis and are replaced by invading osteogenic cells. The PF suture is formed between intramembranous NCC-derived frontal bones. Our study demonstrated that the PF suture undergoes fusion through a process of endochondral ossification as demonstrated by the expression profile of several genes. It is well established that in vivo, the chondrogenic lineage is specified by the transcription factor Sox9, the expression of which is necessarily required for cartilage formation (Akiyama et al., 2002; Bi et al., 2001; Mori-Akiyama et al., 2003). By binding to specific target enhancers on cartilage markers (Type II, IX, and X), CD-RAP and aggrecan, Sox9 protein induces the expression of a chondrocyte phenotype at the early stage of condensation of mesenchymal precursors, which is fundamental to the onset of chondrogenesis (de Crombrugghe et al., 2000). As a first index of chondrogenicity, we have shown expression of Sox9, a marker of precartilage condensation (Ng et al., 1997; Zhao et al., 1997) as well as type I collagen, a molecular marker of undifferentiated chondroprogenitors (Kosher et al., 1986; von der Mark, 1980). Subsequently, the complete absence of type I collagen, together with high level of type II collagen, indicated that the chondrocytes were differentiating in the PF suture prior to closure. Moreover, these differentiated chondrocytes then sustained a series of sequential changes that included conversion to hypertrophic chondrocytes expressing high levels of type X collagen. Furthermore, osteogenesis, as shown by the expression of both type I collagen and Osteocalcin, markers of bone formation, further supported an endochondral ossification within the PF suture. Therefore, we conclude that the cartilage detected within the PF suture is subsequently replaced by bony tissue. However, whether the entire cell population or a small subset of neural crest-derived cells adopt the chondrogenic fate is unknown.

Several questions can be raised from our current work. First, does the endochondral ossification control the entire process of PF suture closure? Second, is the endochondral ossification an evolutionarily conserved pattern of PF suture closure? In rats as well as humans, presence of cartilage tissue in the PF suture before the time of closure has been reported (Manzanares et al., 1988; Moss, 1958). Interestingly, in zebrafish where the PF suture stays patent throughout lifetime, there is no evidence of cartilage formation within the PF suture (Quarto, N., unpublished results). These findings suggest that endochondral ossification during PF suture closure may be a unique feature of mammalian organisms.

**Fig. 7.** Fgf-2 and Fgf-18 expression profile in PF suture complex. A, quantitative real-time PCR revealed a peak of Fgf-2 expression on p9, coinciding with maximum Sox9 peak expression. Expression returned to baseline by p13. B, quantitative real-time PCR reveals an up-regulation of Fgf-18 gene expression starting on p10, the onset of sutural ossification. Maximum expression is seen on p11–13, a period coinciding with a period of maximal bone deposition for suture closure. Only background expression of Fgf-18 was seen by p15, a period where suture closure was mostly completed. C, note, likely as described for Sox9 gene expression in SAG suture (Fig. 3E), no upregulation of Fgf-2 expression is detected in the SAG suture using quantitative real-time PCR. D, temporal expression of key genes involved in PF suture closure. The diagram summarizes the temporal gene expression profiles and differentiation events occurring during PF suture closure.
Fig. 8. Analysis of PF suture phenotype in Sox9 conditional ko mice. A, Sox9\textsuperscript{flOX/WT;Wnt1-Cre} mice were generated by crossing Sox9\textsuperscript{flOX/WT} with Wnt1-Cre mice. Progeny were genotyped by PCR. Mice harboring Sox9\textsuperscript{flOX/WT;Wnt1-Cre} exhibited a hypoplastic craniofacial skeleton with smaller and domed shaped skulls. (Lower panel), fresh calvariae of p10 animals analyzed under stereo microscope (magnification 2.4×) reveals a patent PF suture in the mutant mice (arrow), while clearly showing areas of closure in the wild-type mice (arrow). B, H&E and Safranin-O staining of PF suture sections from p10 mice show an endochondral ossification in the wild-type, while in the mutant mice no area of chondrogenesis or osteogenesis is seen in the endocranial layer (arrowheads). By day p15, complete closure of PF suture is observed in wild type mice, whereas in Sox9\textsuperscript{flOX/WT;Wnt1-Cre} mutant mice PF suture is still open (arrows) (magnification at 63×). C, Alcian blue staining of whole-mount calvariae at p9 reveals chondrogenic domains in the PF suture of WT mice, while is noted absence of these domains in PF suture of Sox9\textsuperscript{flOX/WT;Wnt1-Cre} mice (A, anterior, P, posterior).
and that a chondrogenic event is a “prerequisite” for PF suture closure. In support of the latter hypothesis are our data showing the lack of chondrogenesis events in sagittal and coronal sutures that normally do not undergo closure.

**Sox9 haploinsufficiency in cranial neural crest-derived cells impairs PF suture closure**

Many craniofacial defects can be traced to abnormalities in neural crest biology. The neural crest is a transient migratory population of stem cells derived from the dorsal neural folds at the border between neural and non-neural ectoderm (Le Douarin and Kalcheim, 1999; Mayor et al., 1999). These unique cells are characterized by their extensive migration and ability to generate a large spectrum of cell types (Bronner-Fraser, 1994; LaBonne and Bronner-Fraser, 1999; Selleck et al., 1993).

The PF suture represents a mesenchymal structure of cranial neural crest (CNC) origin. Our initial data demonstrated a temporally-specific and unique up-regulation of Sox9 in the PF suture mesenchyme during the time preceding suture closure. Moreover, the expression of Sox9 was followed by cartilage formation and endochondral ossification. These observations prompted us to examine the potential role of this master regulator of chondrogenesis in the PF suture closure. We asked whether inactivation of Sox9 could affect the proper timing and/or impair PF suture closure. For this purpose, we used Wnt1-Cre Sox9<sup>flo</sup> conditional heterozygotic mice and analyzed the phenotype and the timing of PF suture closure. The Wnt1-Cre Sox9 system has the advantage of distinguishing between neural crest-derived and mesodermal components of cranial skeletogenic mesenchyme and thus, to investigate the tissue origin of endochondral ossification.

In Sox9 haploinsufficient mice, we observed a lack of suture closure when compared to the wild type mice. However, at later stages, an impaired PF suture closure was observed in Sox9 haploinsufficient mice (data not shown), probably as result of a dosage-gene compensation. The observation that PF suture closure was impaired in the Sox9 haploinsufficient mice, strongly indicated that Sox9 is involved in suture closure, possibly by inducing cartilage formation that undergoes endochondral ossification, leading to suture closure. Based on these data, we speculate that a complete knock-out of Sox9 gene in the PF suture may result in a more severe phenotype characterized by both the complete lack of cartilage formation and PF suture closure throughout life-time. Experiments using siRNA technique are underway to test this hypothesis. However, an alternative explanation for the presence of impaired PF suture closure, observed in Wnt1-Cre Sox9<sup>flo</sup> older mice could be that the CNC-derived cells present in the PF suture respecify themselves into an osteoblast lineage, indeed forming patchy bony bridge within the suture.

Akiyama et al. in their study on Wnt1-Cre Sox9<sup>flo</sup> mice showed that inactivation of Sox9 in CNC cells resulted in a complete defect of CNC-derived endochondral bone formation, but that intramembranous bones formed normally. In addition, their experiments strongly suggested that Sox9-null CNC derived cells, which were blocked from differentiating into chondrocytes, expressed instead osteoblast marker genes, suggesting that Sox9-null CNC-derived cells were respecified into an osteoblast lineage. Therefore, at the moment we cannot rule out the possibility that the Sox9-null CNC-derived cells in the PF suture can be respecified into an osteoblast lineage, forming a poor bony bridge within the suture. Thus, the use of Wnt1-Cre Sox9, which is specific to neural crest and some parts of the brain, indicated that the cells contributing to the cartilage formation and subsequent endochondral ossification of PF suture are of neural crest origin. Furthermore, it demonstrated that Sox9 plays an important role in PF suture closing. Therefore, we conclude that neural crest cell determinant genes such as Sox9 regulates PF suture closure. This is to our knowledge the first report describing a specific role of a neural crest cell determinant gene in PF cranial suture patterning and closure. Our work has shown that there is a territory within the PF mesenchymal suture under control of Sox9 gene which induces cartilage differentiation followed by endochondral ossification. This finding supports a model of autonomous endochondral ossification occurring in the skull vault where the intramembranous ossification is a major player.

**Conclusions**

The neural crest derived PF suture is endowed with a sophisticated architecture comprised of two layers of bone: the ectocranial and the endocranial layer. The endocranial layer of PF suture closes during the second week of life. This interesting and unique pattern of PF suture closure is characterized by a sharp and tempo-spatial up-regulated Sox9 gene expression, and chondrogenic domains which mark precise boundaries for the areas of closure within the PF suture. We have presented evidence showing an up-regulation of Sox9 gene expression, followed by a chondrogenesis process occurring within the PF suture during its closure. Moreover, our data demonstrated endochondral ossification as the major event leading to PF suture closure. Finally, haploinsufficiency of Sox9 in NCC-derived cells resulted in a severe impairment of chondrogenesis as well as PF suture closure. These results strongly suggest that the unique expression of Sox9 in the PF suture may provide inductive signal(s) for postnatal PF suture patterning and closure.

**Acknowledgments**

The authors wish to thank Marie-Christine Chaboissier, Andreas Schedl (INSERM U470, Centre de Biochimie, Nice, France) and Benoit de Crombrugghe (University of Texas, M.D. Anderson Cancer Center, USA), for providing...
the Sox9/flox mice. We thank Dr. Karl Sylvester for the critical reading of the manuscript. This work was supported by NIH grants R01DE13194 and R01DE14526 and the Oak Foundation to M.T.L.

References


